I know the battle I am going to have.

Wednesday's conversation with Sahara Fleetwood-Beresford is still with me.

Sahara is one of the most articulate patient advocates I have spoken to. She spends her time helping others navigate a healthcare system that was not built around them. She knows the language. She knows the frameworks. She knows, better than most, exactly what to do.

And then she said this.

"I tell everybody else that you have got to fight for yourself. You have got to advocate for yourself. You have got to use your voice. And I truly believe it. But I often cannot make myself pick up the phone to even make an appointment, because I know the battle I am going to have."

Sahara is not describing a knowledge deficit. She is not describing low health literacy or a lack of awareness or an absence of trust in medicine. She is describing the exhaustion of a system that requires you to fight every single time. That turns every appointment into a negotiation. That asks you to prove, repeatedly, that your experience is real, your symptoms are genuine, and your presence in a clinical setting is warranted.

The industry frames this as a patient engagement problem. How do we get communities to participate? How do we build trust? How do we improve health literacy?

Those are the wrong questions. They locate the problem in the patient. In what the patient knows, feels, or does.

Sahara knows everything. She is the person the system should be listening to. And she cannot pick up the phone.

That is not a patient problem. That is a design problem. And until the people building clinical trials, designing healthcare pathways, and commissioning patient engagement programmes understand the difference, nothing fundamental will change.

This is what Frequency of Exclusion is about. Not the patients who have never engaged. The ones who have engaged, know the system, understand what participation involves, and still cannot sustain it because the cumulative weight of fighting is too heavy to carry every time.

If you missed the conversation with Sahara, it is still available. Watch it and send it to one person who needs to hear that line.

Last week I had a consultation with an innovation hub. I will not name them. They are well-meaning, doing important work, and the person I spoke to was generous with their time and honest with their feedback.

The feedback was essentially this: nobody in that consultation understood what we were building. The suggestions were to look at NIHR, get linked in with Healthwatch, clarify the GDPR position, think about how we compare to competitors.

All reasonable observations in the abstract. None of them the right questions for what Equity Engine actually does.

I said it on that call and I will say it here: when I talk to clinical development teams, they understand immediately. When I talk to people outside the industry, they do not.

I have been thinking about why that is. And I think the answer is this.

Equity Engine is a solution to a problem that only becomes visible if you understand how clinical trial design actually works. How eligibility criteria get written. What a protocol amendment costs. Why a visit schedule that looks reasonable on paper creates dropout rates that sink a study. Why a patient information leaflet featuring a 70-year-old man with grey hair on a golf course signals to an entire community that this trial was not designed for them.

Without that context, Equity Engine looks like a database of patient opinions. And a database of patient opinions is something the innovation ecosystem already has frameworks for evaluating. Healthwatch. NIHR PPIE cohorts. Community engagement consultancies.

But that is not what this is. This is decision-grade evidence that enters the protocol design process at the point where design decisions are still changeable. It is the difference between patient input that decorates a submission and patient data that changes what the submission says.

The people who understand that distinction immediately are clinical development leaders, patient strategy heads, regulatory affairs directors. The people who often do not are the ones sitting in gatekeeping positions across the innovation ecosystem. Innovation hubs. Early-stage investors. Funding bodies. The people deciding which solutions get support, which companies get visibility, which founders get through the door.

And here is what I keep coming back to.

That is the same structural problem we are trying to solve in clinical research.

The people designing clinical trials are often distant from the communities those trials are meant to serve. They make design decisions based on assumptions rather than evidence about how real people live. The result is protocols that look right on paper and fail in practice.

The people evaluating health equity innovation are often distant from the clinical development problem those innovations are trying to solve. They evaluate based on frameworks built for different kinds of solutions. The result is gatekeeping that filters out the things that would actually work.

The same dynamic. The same distance. The same consequences.

I am not saying this to be critical of any individual or organisation. I am saying it because it is a structural issue that affects which health equity solutions get to scale, and which ones stay small not because they do not work but because the people deciding what gets support do not have enough proximity to the problem to recognise the solution.

Something else I said on that call that I want to say here. I am a marketer. I have done this for other companies my whole career. And when it is your own business, when you are trying to explain something that sits at the intersection of clinical research, data infrastructure, community trust, and regulatory compliance, in thirty seconds, to someone who does not share any of those reference points, it is the hardest thing I have ever tried to do.

That is not a reason to stop trying. But it is a reason to name the structural problem honestly. The burden of explanation should not sit entirely with the founder who is closest to the problem. Some of it should sit with the gatekeepers who are furthest from it.

This Wednesday at 2pm UK, 9am ET, we are back with the second episode of Unwritten: Live.

My guest is Ella Balasa. Ella has lived with cystic fibrosis since she was eighteen months old. She has built a consulting career helping biotech and startup companies develop strategies to involve patients in drug and product development. She has served on advisory boards for the Cystic Fibrosis Foundation, the Clinical Trials Transformation Initiative, and PCORI. She knows the system from the inside — as a patient, as a scientist, and as an advisor.

We are going to talk about eligibility criteria. Specifically, the ones that quietly close the door on patients who most need access to new treatments. The ones that look scientifically defensible on paper and function as exclusion mechanisms in practice. And what it would actually look like to design them differently.

Ella is one of the sharpest people working at the intersection of patient advocacy and clinical development. This is a conversation worth making time for.

Wednesday. 2pm UK. 9am ET.

Thanks for reading. This newsletter exists because I believe the right framing, in the right hands, changes decisions. If it did that for you this week, even a little, that is enough.

Speak soon.

Ashish.